Molecular therapies and precision medicine for hepatocellular carcinoma
The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …
an annual incidence of 1 million cases. Genomic studies have established the landscape of …
systemic treatment of hepatocellular carcinoma
M Pinter, M Peck‐Radosavljevic - Alimentary pharmacology & …, 2018 - Wiley Online Library
Background The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a
milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic …
milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic …
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
Background & Aims Treatment of liver cancer remains challenging because of a paucity of
drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is approved …
drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is approved …
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
HY Lim, P Merle, KH Weiss, T Yau, P Ross… - Clinical Cancer …, 2018 - AACR
Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC) …
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC) …
[HTML][HTML] Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC
patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic …
patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic …
Design, synthesis and biological evaluation of 1-hydroxy-2-phenyl-4-pyridyl-1H-imidazole derivatives as xanthine oxidase inhibitors
T Zhang, Y Lv, Y Lei, D Liu, Y Feng, J Zhao… - European journal of …, 2018 - Elsevier
In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic
acid derivatives that presented excellent in vitro xanthine oxidase inhibitory potency. As a …
acid derivatives that presented excellent in vitro xanthine oxidase inhibitory potency. As a …
Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study
WC Yu, KZ Zhang, SG Chen, WF Liu - Medicine, 2018 - journals.lww.com
Efficacy and Safety of apatinib in patients with intermediat... : Medicine Efficacy and Safety of
apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective …
apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective …
A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
A Inoue, T Mizushima, X Wu, D Okuzaki… - Molecular cancer …, 2018 - AACR
We previously demonstrated that miR-29b-3p is a hopeful miRNA-based therapy against
colorectal cancer. In this study, we aimed to clarify a value of miR-29b-1-5p as a next …
colorectal cancer. In this study, we aimed to clarify a value of miR-29b-1-5p as a next …
Integrative omics analyses broaden treatment targets in human cancer
Background Although large-scale, next-generation sequencing (NGS) studies of cancers
hold promise for enabling precision oncology, challenges remain in integrating NGS with …
hold promise for enabling precision oncology, challenges remain in integrating NGS with …
Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
SK Cheon, HP Kim, YL Park, JE Jang, Y Lim… - Molecular …, 2018 - Wiley Online Library
Although MEK blockade has been highlighted as a promising antitumor drug, it has poor
clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have …
clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have …